DelveInsight’s ‘Immune Thrombocytopenia (ITP) – Epidemiology Forecast–2030’ report delivers an in-depth understanding of the ITP, historical and forecasted epidemiology as well as the ITP trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Geography Covered
Study Period: 2017–2030
Disease Overview
Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of immune thrombocytopenia, stem from a low platelet count leading to excessive bleeding.
Click to read more.
Immune Thrombocytopenia (ITP) Epidemiology
DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017.
Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of ITP, Total Diagnosed Prevalent Population of ITP, and Gender-specific Diagnosed Prevalent Population of ITP scenario of ITP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
Request for sample pages.
Immune Thrombocytopenia (ITP) Detailed Epidemiology Segmentation
Visit to know more about the report.
Table of contents
1. Report Introduction
2. Immune thrombocytopenia (ITP)
3. Immune thrombocytopenia (ITP) Current Treatment Patterns
4. Immune thrombocytopenia (ITP) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Immune thrombocytopenia (ITP) Late Stage Products (Phase-III)
7. Immune thrombocytopenia (ITP) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Immune thrombocytopenia (ITP) Discontinued Products
13. Immune thrombocytopenia (ITP) Product Profiles
14. Immune thrombocytopenia (ITP) Key Companies
15. Immune thrombocytopenia (ITP) Key Products
16. Dormant and Discontinued Products
17. Immune thrombocytopenia (ITP) Unmet Needs
18. Immune thrombocytopenia (ITP) Future Perspectives
19. Immune thrombocytopenia (ITP) Analyst Review
20. Appendix
21. Report Methodology
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: www.delveinsight.com/